DMRA missed EPS expectations by 72.64%
Mar 17, 2026, 10:35 AM
58.29%
What does DMRA do
Galecto, a Boston-based biotechnology company with 13 employees, focuses on developing small molecule therapeutics targeting cancer and fibrotic diseases, including GB0139 for Idiopathic Pulmonary Fibrosis. The company went public on October 29, 2020.
Damora Therapeutics (DMRA) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Damora Therapeutics's actual EPS was -$5.23, missing the estimate of -$3.03 per share, resulting in a -72.64% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.